CoChat

An orally available, brain penetrant, small molecule lowers huntingtin levels by enhancing pseudoexon inclusion

Open access
Keller, Caroline Gubser, Shin, Youngah, Monteys, Alex Mas, Renaud, Nicole, Beibel, Martin, Teider, Natalia, Peters, Thomas, Faller, Thomas, St-Cyr, Sophie, Knehr, Judith, Roma, Guglielmo, Reyes, Alejandro, Hild, Marc, Lukashev, Dmitriy, Theil, Diethilde, Dales, Natalie, Cha, Jang-Ho, Borowsky, Beth, Dolmetsch, Ricardo, Davidson, Beverly L., Sivasankaran, Rajeev · 2022 · Nature Communications
Cited by 119

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Huntington’s Disease (HD) is a progressive neurodegenerative disorder caused by CAG trinucleotide repeat expansions in exon 1 of the huntingtin ( HTT ) gene. The mutant HTT (mHTT) protein causes neuronal dysfunction, causing progressive motor, cognitive and behavioral abnormalities. Current treatments for HD only alleviate symptoms, but cerebral spinal fluid (CSF) or central nervous system (CNS) delivery of antisense oligonucleotides (ASOs) or virus vectors expressing RNA-induced silencing (RNAi) moieties designed to induce mHTT mRNA lowering have progressed to clinical trials. Here, we present an alternative disease modifying therapy the orally available, brain penetrant small molecule branaplam. By promoting inclusion of a pseudoexon in the primary transcript, branaplam lowers mHTT protein levels in HD patient cells, in an HD mouse model and in blood samples from Spinal Muscular Atrophy (SMA) Type I patients dosed orally for SMA (NCT02268552). Our work paves the way for evaluating branaplam’s utility as an HD therapy, leveraging small molecule splicing modulators to reduce expression of dominant disease genes by driving pseudoexon inclusion.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-022-28653-6

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 119

Metadata

Authors
Keller, C. G., Shin, Y., Monteys, A. M., Renaud, N., Beibel, M., Teider, N., Peters, T., Faller, T., St-Cyr, S., Knehr, J., Roma, G., Reyes, A., Hild, M., Lukashev, D., Theil, D., Dales, N., Cha, J.-H., Borowsky, B., Dolmetsch, R., Davidson, B. L., & Sivasankaran, R.
Venue
Nature Communications
Published
2022-03-03
Volume
13
Issue
1
Pages
1150-1150
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4221115405
Cited by
119
References
8
FWCI
10.02
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: An orally available, brain penetrant, small molecule lowers huntingtin levels by enhancing pseudoexon inclusion. https://app.cochat.ai/papers/10.1038/s41467-022-28653-6
The paper
Keller, C. G., Shin, Y., Monteys, A. M., Renaud, N., Beibel, M., Teider, N., Peters, T., Faller, T., St-Cyr, S., Knehr, J., Roma, G., Reyes, A., Hild, M., Lukashev, D., Theil, D., Dales, N., Cha, J.-H., Borowsky, B., Dolmetsch, R., . . . Sivasankaran, R. (2022). An orally available, brain penetrant, small molecule lowers huntingtin levels by enhancing pseudoexon inclusion. Nature Communications. https://doi.org/10.1038/s41467-022-28653-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.